The Democratic Republic of the Congo has reported 11,042 Ebola cases and 5,387 deaths, with the Bundibugyo strain spreading across eight provinces.
Conflict, weak healthcare infrastructure and difficulties reaching affected communities have hampered efforts to contain the outbreak.
India's Serum Institute is collaborating with Oxford University on an experimental vaccine candidate being considered for a WHO-supported trial, although no new direct Indian government aid commitment has been publicly confirmed in the sources reviewed.
The Ebola outbreak in the Democratic Republic of the Congo (DRC) has crossed 11,000 confirmed cases, with the death toll nearing 5,400, as health authorities struggle to contain what has become the country's deadliest outbreak. Government data released on Wednesday, November 11, showed that 11,042 people had been infected and 5,387 had died from the Bundibugyo strain of the virus, which has spread across eight of the country's 26 provinces. With no approved vaccine or specific treatment currently available for the strain, the outbreak has exposed serious gaps in the country's public health response, compounded by armed conflict, limited access to healthcare and mistrust among local communities.
The outbreak was declared on May 15, 2026, and has since expanded beyond the DRC, with cases also reported in Kenya and Nigeria. The World Health Organization (WHO) has warned that sustained transmission in the DRC, particularly in areas affected by insecurity, continues to pose a significant public health challenge. The crisis has also renewed attention on international cooperation, including the potential contribution of Indian vaccine research and manufacturing.
Conflict, Weak Healthcare System Hamper Ebola Containment
The Bundibugyo virus outbreak has proved particularly difficult to contain because of the security and humanitarian conditions in the affected regions. Fighting in eastern DRC, especially in Ituri and North Kivu, has restricted the movement of healthcare workers and made it difficult to reach patients and trace their contacts. Poor road infrastructure, strained medical facilities and attacks on health workers have further complicated efforts to isolate infected people and prevent transmission.
The scale of transmission has also raised concerns about delayed diagnosis and deaths occurring outside treatment centres. In its November 6 update, the WHO reported 10,668 confirmed cases and 5,198 deaths in the DRC as of November 3, with 335 of the 512 deaths recorded since October 21 occurring in communities rather than treatment centres. The agency said this highlighted the difficulties in identifying infections early and ensuring that patients received timely medical care.
The Bundibugyo virus is one of the distinct species of Ebola-causing viruses. It spreads through direct contact with the blood or other bodily fluids of an infected person, or contaminated materials. Early symptoms, including fever, fatigue, muscle pain and headaches, can resemble those of other illnesses, making timely identification difficult. The strain has no approved vaccine or specific treatment, although supportive medical care can improve a patient's chances of survival. The current outbreak has a crude case fatality ratio of close to 49 per cent, according to WHO data.
The WHO has supported the launch of the Tumaini vaccine trial in Bunia, in Ituri province, which began enrolling participants on October 23. The Phase 2/3 trial initially began by evaluating the Ervebo vaccine, which is approved for a different Ebola virus species, but whose effectiveness against Bundibugyo remains uncertain. WHO experts have since recommended adding two experimental candidates: ChAdOx1, developed by the University of Oxford in collaboration with the Serum Institute of India, and Moderna's mRNA-1469. Their inclusion is subject to national approvals.
India's Potential Role In Ebola Response
India could contribute to the longer-term response through its vaccine research and manufacturing capabilities, particularly because the Serum Institute of India is involved in developing one of the experimental candidates being considered for the Bundibugyo outbreak. The ChAdOx1 vaccine, developed by Oxford University in partnership with the Pune-based institute, has been recommended for inclusion in the Tumaini trial. If it receives the necessary approvals and demonstrates safety and efficacy, the candidate could become an important addition to efforts to protect people against the strain.
However, there is a distinction between India's involvement in vaccine development and a direct government assistance programme for the DRC. There has been no publicly confirmed announcement in the sources reviewed of a new Indian government commitment to send emergency medical teams, supplies or financial assistance specifically for this outbreak. India's documented response so far has focused on domestic preparedness. In May, the Union Health Ministry said it had strengthened surveillance at international airports and other points of entry, issued guidelines to states and hospitals, and coordinated with agencies including the National Centre for Disease Control and the Indian Council of Medical Research.
The Indian government had also said in May that no Bundibugyo Ebola case had been reported in the country at that time. Its preparedness measures included screening international travellers, laboratory testing protocols, isolation arrangements and infection-control guidelines. These steps were intended to reduce the risk of the virus entering India, rather than constitute direct assistance to the affected country.
The immediate challenge, however, remains controlling transmission in the DRC. The WHO has called for stronger surveillance, contact tracing, infection prevention and cross-border coordination, while warning against travel and trade restrictions against affected countries. For India, the vaccine partnership offers a possible avenue for contributing to the international response, but whether that translates into a wider assistance effort will depend on further developments and decisions by the government and its partners.
